Zepbound linked to lower healthcare costs for older adults

The analysis, which examined data from over 15,000 adults, found that the financial benefits of the treatment become more pronounced over time. While costs were approximately 15% lower at the six-month mark compared to untreated peers, that gap widened to as much as 38% after one year. Researchers attributed these savings primarily to a reduction in acute care requirements, including fewer admissions to hospitals and emergency departments.

Ilya Yuffa, executive vice president at Eli Lilly, noted that the data provides a clear look at the economic impact of obesity management in an aging population. The study utilized Komodo’s Healthcare Map to track patients who initiated treatment between late 2023 and 2025, matching them against untreated individuals with similar clinical profiles. Although the study excluded the direct price of the medication from its calculations, the results indicate that the savings generated through improved patient health could eventually cover the monthly treatment expenses associated with the Medicare GLP-1 Bridge program.